Chronic Kidney Disease in Balkan Countries—A Call to Action for Timely Diagnosis and Monitoring

Igor Mitić 1,2, Mario Laganović 3,*, Ivelina Marinova 4, Nina Gancheva 5, Valentina Nakić 6, Dragana Melentijevic 7, Emil Paskalev 4, Rajko Vajd 8 and Andrej Škoberne 9,10,*

1 Medical Faculty, University of Novi Sad, Hajduk Veljkova 3, 21137 Novi Sad, Serbia
2 Clinic of Nephrology and Clinical Immunology, Clinical Centre of Vojvodina, Hajduk Veljkova 1, 21137 Novi Sad, Serbia
3 Department of Internal Medicine, University Hospital Merkur, Zajčeva 19, 10000 Zagreb, Croatia
4 Clinic of Nephrology and Transplantation, University Hospital “Alexandrovska”, Sveti Georgi Sofiyski 1, 1431 Sofia, Bulgaria
5 Medical Diagnostic Center 1, Ploshtad Otets Paisiy 40, 9000 Varna, Bulgaria
6 Health Center Gajnice, Mahatme Gandhija 5, 10090 Zagreb, Croatia
7 Public Health Center “Dr Simo Milošević”, Požeska 82, 11000 Belgrade, Serbia
8 Community Health Centre Medvode, Ostroviharjeva Ulica 6, 1252 Medvode, Slovenia
9 Department of Nephrology, University Medical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia
10 Medical Faculty, University of Ljubljana, Vrazov Trg 2, 1000 Ljubljana, Slovenia
* Correspondence: mlaganovic@gmail.com (M.L.); andrej.skoberne@kclj.si (A.Š.)

Abstract: Chronic kidney disease (CKD) is a serious illness with important consequences for patients and health systems. Estimation of prevalence and incidence, especially in early stages, is difficult due to a lack of epidemiological studies and consolidated registries. In general, the disease awareness is low, and thus CKD is not timely diagnosed in most cases. Robust screening programs are not implemented in Eastern European countries. A panel consisting of Primary Care Physicians and Nephrologists from Bulgaria, Croatia, Serbia, and Slovenia virtually met in December 2021 to discuss current CKD awareness and diagnostic approaches in the Balkan area. The meeting resulted in specific calls to action in the region to improve the number and quality of epidemiology studies and the level of awareness among patients and medical communities, as well as implementation of screening programs in high-risk populations. Collaboration between specialists was acknowledged as a crucial driver for optimal management of patients with CKD. Joint efforts are required to persuade healthcare authorities to establish specific policies for better care of kidney patients.

Keywords: chronic kidney disease; CKD; screening; awareness; diagnosis; monitoring; call to action; Balkan; Eastern Europe

1. Introduction

Chronic kidney disease (CKD) is a severe condition affecting approximately 800 million people (10%) of the world’s population [1], out of which 75–100 million are in Europe [2,3]. An accurate estimation of its prevalence and incidence, especially in the initial stages, is complicated by the lack of epidemiologic studies in the region. Decline of kidney function may be asymptomatic in early stages and probably many years after, thus leaving it far from the spotlight of public and medical communities’ attention. CKD is currently considered one of the most neglected chronic diseases [4].

Due to the increasing incidence of cardiovascular (CV) disease and diabetes in an aging population, representing the high-risk populations, the progression to end-stage renal disease (ESRD) is estimated to increase by 5–8% each year [5]. However, the advanced stages requiring dialysis or other renal replacement therapies are only a part of the problem. Of 100 persons with CKD, only 1 will require dialysis or transplantation [3,4]. Due to its enormous effect on heightening the risk of CV diseases and events, CKD ranked as the
10th leading cause of death globally in 2019 [1]. If appropriate measures are not taken urgently, the projection is that CKD will rise among the top 5 causes of death by 2040, ahead of all cancer types and diabetes [4]. Mortality rates are rising from the earlier stages (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73m² or normal eGFR with albuminuria) [6,7] and add to the mortality risk of the associated diseases.

Disease awareness among patients is low. A recent paper from Germany showed that almost 80% of patients diagnosed with CKD at an early stage and 30% in the later stages were not aware of their disease [8]. A study performed in Poland [9] in an elderly population showed a prevalence of CKD of 29.4% with a level of disease awareness of only 3.2%. In the United States, 9 out of 10 people with CKD do not know they have this disease [10]. Gaps in education about the diagnosis and the implications may be due to inefficient testing, communication of the results or understanding of the information.

Although screening of the general population is debatable [11,12], the regular assessment of serum creatinine and albuminuria in high-risk groups (elderly patients with arterial hypertension, diabetes, cardiovascular diseases or familial history of CKD) was suggested as a more cost-efficient approach. Most Western European countries have implemented national screening programs for CKD in patients with diabetes and hypertension [1], but screening remains suboptimal in some countries in Central and Eastern Europe (CEE) due to limited infrastructure and resources, social, educational, and cultural differences [13].

The alarming rise in prevalence and mortality rate linked to CKD in the CEE region [2,13] requires an immediate call to action aiming to increase disease prevention and its early identification and treatment. The gaps that should be addressed urgently include development of structured simple screening, a diagnostic and treatment algorithm on a national and/or regional level endorsed by professional societies and designed for implementation in routine practice. In this manuscript we present the Balkan initiative focused on screening and diagnosis of CKD in the region.

2. Materials and Methods

Driven by the need to challenge the status quo, a panel consisting of eight experts involved in the management of patients with CKD from four countries in CEE virtually met in December 2021 to discuss the need to improve CKD awareness and diagnosis in the Balkan area. Four primary care professionals (PCPs) and four nephrologists from Bulgaria, Croatia, Serbia, and Slovenia participated in this meeting. We divided the CKD issues into three sections that were discussed independently at the meeting: epidemiology, risk factors and disease awareness, diagnosis, and treatment. For each of these topics, representatives described the current situation in their respective countries and fields of profession. This included relevant data from each country, the current state of the healthcare system in general, and the fields of primary care and nephrology in particular, including relevant logistical and financial issues. Relevant legal and insurance issues were also discussed. After these initial presentations, overlapping issues that were common in all of the participating countries were identified and written down in order to summarize the key points of the current status of each topic. Afterwards, a framework for tackling these challenges and problems was discussed and key messages were formed in order to form the specific calls to action for each topic. All of the points presented in the results were included after unanimous agreement among the participants. Our main aim was to identify and prioritize key challenges in the management of CKD and to provide possible solutions that would be relevant in our region and possibly beyond in similar countries.
3. Results
3.1. Epidemiology
3.1.1. Current Status
Robust epidemiology data are lacking in the region. We extracted CKD prevalence rates in the Balkan countries from a recent international publication [3] that had established these figures using different data sources (published literature, vital registration systems, end-stage kidney disease registries, and household surveys). In the past 30 years, the change in CKD prevalence rates in the participating Balkan countries ranged from −1.1% to 2.6%, whereas the death rates due to CKD increased up to 45%, except for Slovenia, where the calculated reduction of mortality rate was approximately 30% (Table 1).

Table 1. CKD prevalence and CKD-related mortality rates in the four countries of the Balkan region, as of 2017.

| Country/Region | Count Age-Standardized Rate per 100,000 | Percentage Change in Age-Standardized Rates between 1990 and 2017 |
|----------------|----------------------------------------|-------------------------------------------------------------|
| Bulgaria       | 981,339 (909,610 to 1,061,687)          | 2.6% (−0.7 to 5.9)                                          |
|                | 8000 (7420 to 8630)                     |                                                             |
| Croatia        | 562,778 (520,865 to 610,153)           | 1.2% (−3.1 to 6.2)                                          |
|                | 7779 (7206 to 8390)                     |                                                             |
| Serbia         | 1,142,513 (1,063,208 to 1,237,929)     | −0.5% (−4.1 to 3.3)                                         |
|                | 8421 (7846 to 9069)                     |                                                             |
| Slovenia       | 266,527 (247,205 to 289,578)           | −1.1% (−5.7 to 3.2)                                         |
|                | 7581 (7056 to 8179)                     |                                                             |
| Central Europe | 13,951,402 (12,930,450 to 15,136,020)  | −2.7% (−6.2 to 1.4)                                         |
|                | 7659 (7115 to 8282)                     |                                                             |

UI, uncertainty interval. These data had been taken from [3].

This is most likely related to the reduction of CV mortality in Slovenia, where the age-standardized CV mortality rate had dropped from 557.4 deaths per 100,000 population in 1990 to 222.4 deaths per 100,000 population in 2017 in men, and from 371.5 deaths per 100,000 population in 1990 to 153.1 deaths per 100,000 population in 2017 in women [14,15]. A similar improvement in CV mortality has been observed when the whole population of the EU region is considered.
Nevertheless, incidence, prevalence, and mortality rates by CKD stage and other relevant factors (age, comorbidities) are not available in the region. Published literature indicates a higher prevalence of CKD stages G3–G5 and a lower prevalence of renal replacement therapies in Eastern Europe compared to Western countries [16]. The difference cannot be fully explained by the difference in mortality rates or the incidence of different risk factors for reduced kidney function.

3.1.2. Call to Action

- Design and implement an epidemiology study across the Balkan region to collect standardized data on the incidence and prevalence of early stages and causes of CKD. A unique research protocol and uniform data collection and reporting would allow building real-world evidence across the Balkan region, further exploring the variability across countries and informing management strategies based on reliable data.
- Expand existing reporting protocols and registries to include all CKD patients, irrespective of stage of the disease.
- Discuss possibilities to extract retrospective data (serum creatinine and albuminuria) from electronic files and use them as benchmark for epidemiology studies.

3.2. Risk Factors and Disease Awareness

3.2.1. Current Status

In general, the level of CKD awareness is low in the general population and variable in the medical community. Usually, educational information related to kidney diseases are provided annually in different media related to World Kidney Day, by representatives of national professional medical societies. In 2021, the campaigns and webinars for patients organized by the Croatian Society of Nephrology were appreciated by the international officials and included in the Champions’ Report [17]. In Slovenia, high awareness in the medical community is maintained through regular activities dedicated to primary care physicians and medical residents. Despite increasing of online communications for different health conditions during the Coronavirus disease-19 (COVID-19) pandemic, CKD did not gain a higher visibility in the region.

3.2.2. Call to Action

- Advocate for development and implementation of professional awareness campaigns for patients and medical professional communities.
- Increase media presence of national key opinion leaders to enhance education regarding primary and secondary prevention of CKD.
- Address specifically high-risk populations and collaborate with patient organizations and medical societies to improve recognition of chronic conditions that are risk factors for CKD.
- Promote a unitary and coherent communication strategy to European and national professional societies to streamline education of their members during regular scientific meetings and webinars.

3.3. Diagnosis and Treatment

3.3.1. Current Status

Diagnosis of CKD is based on a persistent reduction of eGFR and/or markers of kidney damage, including high urine albumin-creatinine ratio (UACR) or urine protein-creatinine ratio (UPCR) (Table 2) [18].
Table 2. Criteria for diagnosis (A) and staging (B) of CKD.

### A. Diagnosis of CKD

One or more markers of kidney damage present for >3 months

- Albuminuria (UACR >30 mg/g [>3 mg/mmol] or proteinuria (UPCR > 150 mg/g [> 15 mg/mmol])
- Urine sediment abnormalities
- Electrolyte and other abnormalities due to tubular disorders
- Structural abnormalities detected by imaging and/or biopsy

OR

eGFR <60 mL/min/1.73 m² persistently present >3 months

### B. Staging of CKD

| Stage | eGFR values (mL/min/1.73 m²) |
|-------|-----------------------------|
| G1    | ≥90                         |
| G2    | 60–89                       |
| G3a   | 45–59                       |
| G3b   | 30–44                       |
| G4    | 15–29                       |
| G5    | <15                         |

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; UACR, urinary albumin-creatinine ratio; UPCR, urinary protein-creatinine ratio.

No general CKD screening programs aimed at identifying the presence of the disease in the general population without risk factors are currently available in any of the four participating countries. However, serum creatinine and albuminuria or proteinuria are routinely measured in high-risk patients, like those with diabetes, arterial hypertension or CV diseases. For chronic patients, annual blood and urine analysis are reimbursed in all countries, however no information could be provided on the actual assessment in overall or high-risk populations. Nevertheless, in the past years, the amount of laboratory testing decreased due to reluctance to physically access the healthcare facilities induced by COVID-19. Despite being long recognized by healthcare professionals as an unmet need, the screening protocols for CKD are currently not being employed successfully.

In all countries in the Balkan region, CKD is diagnosed by PCP or other specialist (e.g., endocrinologist, cardiologist, urologist, or internal medicine specialist) and confirmed, when needed, by the nephrologist. Most patients are referred to a nephrologist in the later stages, mainly for complications and assessment of eligibility for renal replacement therapies. Major challenges in CKD management and gaps in the referral pathway are summarized in Table 3. Despite differences in monitoring strategies adopted in each country, medical and laboratory follow-up is usually performed twice per year, the frequency depending on the severity of the CKD and comorbidities.

Table 3. Current challenges in diagnosis and treatment of CKD in the Balkan countries.

### Challenges in Diagnosis

- Limited access to healthcare systems during COVID-19 pandemic
- Limited reimbursement of serum creatinine and albuminuria/proteinuria testing in some cases
- Quantitative testing of albuminuria and proteinuria is not available in some settings of primary care
- No uniform frequency assessment of serum creatinine and albuminuria/proteinuria in high-risk population
Table 3. Cont.

| Challenges in Treatment                                                                 |
|------------------------------------------------------------------------------------------|
| • Lack of reimbursement of SGLT2 inhibitor (dapagliflozin) in CKD without diabetes in some cases |
| • Low number of nephrologists available for referral and CKD treatment                      |

| Gaps in the Referral Pathway                                                                 |
|--------------------------------------------------------------------------------------------|
| • A limit on the number of referrals by PCP per year to nephrologist in some cases          |
| • Limited timely referral from endocrinologists, cardiologists, and other specialties treating high-risk patients |
| • Long waiting times from referral to secondary/tertiary care                                |
| • No clear and simple algorithms of referral indication based on cut-of eGFR and UACR/UPCR |
| • Kidney health network is not available or insufficiently developed                        |

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; SGLT2—sodium-glucose transporter 2; UACR, urinary albumin-creatinine ratio; UPCR, urinary protein-creatinine ratio.

Current pharmacologic approaches in CKD include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and diuretics. The level of reimbursement is variable (from 25–50% in Bulgaria to 100% in Croatia and Slovenia). In 2021, dapagliflozin was granted approval in Europe for the treatment of adults with CKD [19] irrespective of diabetes status, becoming the first sodium-glucose transporter 2 (SGLT2) inhibitor with this indication. Slovenia is the only country in the region where dapagliflozin is reimbursed for the indication in CKD. In general, the treatment is initiated by nephrologists according to local and international guidelines and continued by PCPs based on the national protocols however, initiation by PCPs is possible and should be encouraged in situations where reimbursement is provided in this setting.

3.3.2. Call to Action

- Develop and implement screening programs in high-risk populations to allow diagnosis in early stages and adequate management to slow the decline of renal function (Figure 1).
- Develop simple algorithms for risk assessment, diagnosis, and referral to nephrologists.
- Include CKD risk assessment and diagnostic criteria in all relevant communications, and scientific meetings and webinars.
- Promote reporting on laboratory results of eGFR and UACR/UPCR in all patients with serum creatinine and albuminuria or proteinuria assessment.
- Create multidisciplinary working groups (nephrologist, endocrinologist, cardiologist, PCP) to coordinate implementation of CKD-related activities and lead high-level discussions to include CKD on the agenda of decision makers.
  - Create the framework for structured collaboration of multidisciplinary team in national and regional kidney networks
  - Empower PCPs to initiate and monitor treatment in CKD
  - Increase number of nephrologists to treat CKD in all stages
  - Provide reimbursement of treatments with strong and reliable results on mortality and renal function
  - Share best practices of diagnosis and treatment between countries and institutions
  - Collaborate with specialists in pharmaco-economics to assess the cost-effectiveness of early diagnosis and timely treatment in CKD
4. Discussion

CKD is an emerging condition that will have a major impact on public health in most countries around the world. In parallel with the rise of incidence of CKD, we are also witnessing significant progress in diagnostic methods and therapeutic approaches. New biomarkers have been discovered that could enable a more reliable and accurate identification of kidney disease patients, particularly those with a high risk of progression [20,21]. New technologies are also being employed to tackle the problem of CKD. Nanotechnology is being used in research settings as a tool to identify and treat diverse kidney diseases [22,23] along with new genetic technology [24,25]. New treatment strategies are also emerging. The recognition of the importance of complement activation for progression of many kidney diseases has led to the development of a number of new medications targeting complement pathways [26]. The recognition that mitochondria play an
important role in kidney diseases has also led to new paradigms for CKD treatment [27,28]. In spite of all this exciting progress, we are still insufficient in the most basic aspects of CKD management—early diagnosis and early treatment with therapy that is already available.

This is the first meeting where experts from Balkan countries discussed the challenges in CKD awareness, diagnosis and treatment, and outlined key points of specific calls to action. CKD remains undiagnosed to a large extent in Balkan countries. Although the general understanding is that severity comes with higher stages, the public and most medical communities are not informed about negative consequences and mortality risk in early stages. Despite economic and cultural differences between countries, main unmet needs in the region are similar and related to education, awareness, epidemiology studies, screening protocols, and simple algorithms for diagnosis and referral.

The onset and progression of CKD can be prevented. Efficient elimination and control of risk factors should be one main goal of education and clinical interventions [29] to delay worsening of the disease and mortality. The associated costs in late stages of the disease are considered “catastrophic” for the healthcare systems, therefore early detection and management are crucial.

Each action suggested for improvement of CKD management requires consistent efforts and a strategic approach. The experts will act as leading voices in each country and in the region to gather resources and knowledge to plan, develop, and implement available guidelines and best practices adapted to the local context. Additionally, multidisciplinary teams should be involved in creation and enhancement of kidney networks both locally and regionally to delay and prevent disease progression. Kidney health should be brought in the focus of public health authorities, medical professional societies, and general population to improve screening, diagnosis, and timely treatment of this chronic disease with significant consequences. Finally, we believe that cooperation amongst different countries in order to share experience on practical approaches that actually work in real-life situations is one of the best ways of tackling the reality of an emerging CKD epidemic.

Author Contributions: I.M. (Igor Mitić) contributed to the conception and design of the study, the acquisition of the data, the analysis and interpretation of the data, as well as drafting the manuscript. M.L. contributed to the conception and design of the study, the acquisition of the data, the analysis and interpretation of the data, as well as drafting the manuscript. I.M. (Ivelina Marinova) contributed to the acquisition, analysis and interpretation of the data. N.G. contributed to the acquisition, analysis and interpretation of the data. V.N. contributed to the acquisition, analysis and interpretation of the data. D.M. contributed to the acquisition, analysis and interpretation of the data. E.P. contributed to the conception and design of the study, the acquisition of the data, the analysis and interpretation of the data. A.Š. contributed to the conception and design of the study, the acquisition of the data, the analysis and interpretation of the data. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors have read and agreed to the published version of the manuscript.

Funding: This publication was supported by AstraZeneca UK Limited, Branch Office in Slovenia, Ljubljana, Slovenia (AstraZeneca Slovenia).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Table 1 includes data taken without any change from a published source (GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395, 709–733. doi: 10.1016/S0140-6736(20)30045-3). Permission from Elsevier to use the data has been obtained prior to manuscript submission (Creative Commons Attribution License available at: https://creativecommons.org/licenses/by/4.0/; last accessed on 16 June 2022).
Acknowledgments: Medical writing assistance was provided by Raluca Voicu of MedInteractiv Plus (Bucharest, Romania) and was funded by AstraZeneca Slovenia.

Conflicts of Interest: All authors received speaker fee and advisory board consultancy fee from AstraZeneca. Valentina Nakić also received an educational grant from AstraZeneca. The virtual expert meeting was organized by AstraZeneca. AstraZeneca had no role in the design or interpretation of data included in the manuscript.

Abbreviations

CEE—Central and Eastern Europe, CKD—chronic kidney disease, CV—cardiovascular, eGFR—estimated glomerular filtration rate, ESRD—end-stage renal disease, EU—European Union, KDIGO—Kidney Disease: Improving Global Outcomes, PCP—primary care professional, SGLT2—sodium-glucose transporter 2, UACR—urinary albumin-creatinine ratio, UI—uncertainty interval, UPCR—urinary protein-creatinine ratio.

References

1. Global Health Kidney Atlas, 2nd Edition. 2019. Available online: https://www.theisn.org/initiatives/global-kidney-health-atlas/ (accessed on 25 March 2022).
2. European Kidney Health Alliance Call to Action. Available online: https://ekha.eu/blog/ekha-launches-a-call-to-action-to-improve-ckd-prevention-treatment-and-care-in-the-aftermath-of-covid-19/ (accessed on 25 March 2022).
3. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020, 395, 709–733. [CrossRef]
4. Vanholder, R.; Annemans, L.; Bello, A.K.; Bikbov, B.; Gallego, D.; Garsevoort, R.T.; Lameire, N.; Luyckx, V.A.; Norušiene, E.; Oostrom, T.; et al. Fighting the unbearable lightness of neglecting kidney health: The decade of the kidney. Clin. Kidney J. 2021, 14, 1719–1730. [CrossRef] [PubMed]
5. Bennett, L. Changing European CKD trends: A call to action. J. Ren. Care 2007, 33, 148–152. [CrossRef] [PubMed]
6. Chronic Kidney Disease Prognosis Consortium; Matsushita, K.; van der Velde, M.; Astor, B.C.; Woodward, M.; Levey, A.S.; de Jong, P.E.; Coresh, J.; Garsevoort, R.T. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010, 375, 2073–2081. [CrossRef]
7. Vanholder, R.; Massy, Z.; Argiles, A.; Špasovski, G.; Verbeke, F.; Lameire, N. European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transpl. 2005, 20, 1048–1056. [CrossRef]
8. Stolpe, S.; Kowall, B.; Scholz, C.; Stung, A.; Blume, C. High unawareness of Chronic Kidney Disease in Germany. Int. J. Environ. Res. Public Health 2021, 18, 1752. [CrossRef]
9. Chuđek, J.; Wieczorowska-Tobis, K.; Zejda, J.; Broczek, K.; Skalska, A.; Zdrojewski, T.; Wiecek, A. The prevalence of chronic kidney disease and its relation to socioeconomic conditions in an elderly Polish population: Results from the national population-based study PoSenior. Nephrol. Dial. Transpl. 2014, 29, 1073–1082. [CrossRef]
10. Chronic Kidney Disease in the United States. 2021. Centers for Disease Control and Prevention, US Department of Health and Human Services. 2021. Available online: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html (accessed on 5 April 2022).
11. Komenda, P.; Rigatto, C.; Tangri, N. Screening strategies for unrecognized CKD. Clin. J. Am. Soc. Nephrol. 2016, 11, 925–927. [CrossRef]
12. Vanholder, R.; Annemans, L.; Brown, E.; Gansevoort, R.; Gout-Zwart, J.J.; Lameire, N.; Morton, R.L.; Oberbauer, R.; Postma, M.J.; Tonelli, M.; et al. European Kidney Health Alliance. Reducing the costs of chronic kidney disease while delivering quality health care: A call to action. Nat. Rev. Nephrol. 2017, 13, 393–409. [CrossRef]
13. Sever, M.S.; Jager, K.J.; Vanholder, R.; Stengel, B.; Haramat, J.; Finne, P.; Tesař, V.; Barbulushi, M.; Bumblytė, I.A.; Zakharova, E.; et al. A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. Clin. Kidney J. 2020, 14, 23–35. [CrossRef]
14. Zaletel, M.; Vardič, D.; Hladnik, M. (Eds.) Zdravstveni Statistični Letopis 2013; Nacionalni INštitut za Javno Zdravje: Ljubljana, Slovenia, 2016. Available online: https://www.nijz.si/sl/publikacije/zdravstveni-statistichni-letopis-2013 (accessed on 5 April 2022).
15. Zaletel, M.; Vardič, D.; Hladnik, M. (Eds.) Zdravstveni Statistični Letopis Slovenije 2019; Nacionalni INštitut za Javno Zdravje: Ljubljana, Slovenia, 2021. Available online: https://www.nijz.si/sl/publikacije/zdravstveni-statistichni-letopis-2019 (accessed on 5 April 2022).
16. Carriazo, S.; Ortiz, A. European East-West divide in kidney disease: The need to understand the drivers of chronic kidney disease outcomes. Clin. Kidney J. 2020, 14, 1–4. [CrossRef] [PubMed]
17. Impact Report of WKD 2021. Available online: https://www.worldkidneyday.org/impact-report-2021/ (accessed on 11 April 2022).
18. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013, 3, 1–150.
19. Forxiga (Dapagliflozin) Summary of Product Characteristics. 2022. Available online: https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf (accessed on 11 April 2022).

20. Rysz, J.; Głuba-Brzózka, A.; Franczyk, B.; Jablonowski, Z.; Ciałkowska-Rysz, A. Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. *Int. J. Mol. Sci.* 2017, 18, 1702. [CrossRef] [PubMed]

21. Mizdrak, M.; Kumrić, M.; Tičinović Kurir, T.; Božić, J. Emerging Biomarkers for Early Detection of Chronic Kidney Disease. *J. Pers. Med.* 2022, 12, 548. [CrossRef]

22. Aziz Eftekhari, A.; Dizaj, S.M.; Ahmadian, E.; Przekora, A.; Khatibi, S.M.H.; Ardalan, M.; Vahed, S.Z.; Valiyeva, M.; Mehraliyeva, S.; Khalilov, R.; et al. Application of Advanced Nanomaterials for Kidney Failure Treatment and Regeneration. *Materials* 2021, 14, 2939. [CrossRef]

23. Dizaj, S.M.; Eftekhari, A.; Mammadova, S.; Ahmadian, E.; Ardalan, M.; Davaran, S.; Nasibova, A.; Khalilov, R.; Valiyeva, M.; Mehraliyeva, S.; et al. Nanomaterials for Chronic Kidney Disease Detection. *Appl. Sci.* 2021, 11, 9656. [CrossRef]

24. Jelaković, B.; Dika, Ž.; Arlt, V.M.; Stiborova, M.; Pavlović, N.M.; Nikolić, J.; Colet, J.M.; Vanherweghem, J.L.; Nortier, J.L. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid. *Semin. Nephrol.* 2019, 39, 284–296. [CrossRef]

25. Groopman, E.E.; Rasouly, H.M.; Gharavi, A.G. Genomic medicine for kidney disease. *Nat. Rev. Nephrol.* 2018, 14, 83–104. [CrossRef]

26. Willows, J.; Brown, M.; Sheerin, N.S. The role of complement in kidney disease. *Clin. Med.* 2020, 20, 156–160. [CrossRef]

27. Granata, S.; Dalla Gassa, A.; Tomei, P.; Lupo, A.; Zaza, G. Mitochondria: A new therapeutic target in chronic kidney disease. *Nut. Metab.* 2015, 12, 49. [CrossRef]

28. Eirin, A.; Lerman, A.; Lerman, L.O. The Emerging Role of Mitochondrial Targeting in Kidney Disease. *Handb. Exp. Pharmacol.* 2017, 240, 229–250. [CrossRef] [PubMed]

29. Li, P.K.-T.; Garcia-Garcia, G.; Lui, S.-F.; Andreoli, S.; Fung, W.W.-S.; Hradsky, A.; Kumaraswami, L.; Liakopoulos, V.; Rakhimova, Z.; Saadi, G.; et al. Kidney health for everyone everywhere—from prevention to detection and equitable access to care. *Blood Purif.* 2021, 50, 1–8. [CrossRef] [PubMed]